Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-30

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will examine the effectiveness of a decellularized dermal matrix (i.e., DermGEN™) in improving wound healing, quality of life and associated costs of treatment of DFUs in First Nations people living in the Northwestern Ontario Communities. First Nations people with active diabetic foot (DFU) ulcer attending a wound care clinic located at the Rainy River district office. An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment

NCT02184455

Diabetes Type I Diabetes Type II

COMPLETED PHASE1

Acellular Dermal Allograft for Chronic Diabetic Wounds

NCT06227520

Wound Heal Diabetic Foot Ulcer

NOT_YET_RECRUITING NA

Diabetic Foot Ulcers Microbiome and Pathogen Identification

NCT05556954

Foot Ulcer Diabetes Mellitus Wound

COMPLETED

Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer

NCT00521937

Diabetes Foot Ulcer

UNKNOWN PHASE3

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

NCT00387101

Diabetic Foot Ulcer

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Ulcer Foot Ulcer Healing Diabetic Foot Ulcer Non-healing Wound Wound of Skin Wound; Foot Tissue Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Masking cannot be accomplished as one intervention will require application of an advanced wound care product (DermGEN™) and the other arm (control) will not receive the intervention. This will be quite obvious to all.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

The standard of care includes physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type PROCEDURE

debridement, wound dressings, offloading

DermGEN™

A decellularized dermal matrix created from donated human skin. This arm will receive the same care as the Standard of Care control arm-physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment-with the addition of DermGEN™ onto the wound at the first visit.

Group Type EXPERIMENTAL

DermGEN™

Intervention Type OTHER

Decellularized human dermal matrix created from donated human skin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care

debridement, wound dressings, offloading

Intervention Type PROCEDURE

DermGEN™

Decellularized human dermal matrix created from donated human skin

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acellular Dermal Matrix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant and social support (e.g., family, caregiver) ready and willing to participate and comply with follow-up regime
* Participant willing to be involved in self-care (e.g., keep dressing dry at home) required during treatment
* Participant willing to wear Total Contact Cast (TCC) for wound off-loading during treatment
* Participant or legal representative has read and signed the informed consent form
* Documented stable Type I or II diabetes (HbA1C between 5.0 to 10 mmol/L within 1 month prior to Day 0)
* Ulcer has been present for a minimum of 2 weeks as of Day 0
* Ulcer area is ≥2 cm2 prior to debridement at Day 0 of study
* Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule
* Ulcer is free of dead tissue and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0
* Adequate perfusion to the extremity determined by at least one of the following:

Palpable pedal pulses, Transcutaneous oxygen measurement at the dorsum of the foot ≥30 mm Hg, Ankle-brachial index ranging from 0.8 to 1.2, At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries

Exclusion Criteria

* The individual has any condition that seriously compromises their capacity to provide consent and answers questions related to this study.
* Untreated infection of soft tissue or bone and/or autoimmune connective tissue disorders
* Ulcer is over Charcot deformity (joints deformity of foot and ankle common in people with diabetes)
* Body mass index ≥50 kg/m2
* Ulcer is not classified as diabetes-related
* Ulcer has tunnels or sinus tracts that cannot be completely debrided
* Medical condition(s) that in the investigators' opinion make the patient inappropriate for study (e.g active liver disease)
* Presence of malignant disease not in remission for 5 years or more
* The individual is undergoing chemotherapy/radiation therapy
* The individual received radiation therapy within 30 days of Day 0 of study
* The individual is taking an immunosuppressant medication (e.g., corticosteroids, immunosuppression or cytotoxic agents), or is anticipated to require such agents during study
* Presence of acute or chronic hepatitis, liver disease, anemia, serum albumin \<2.0 gm/dL, or has alkaline phosphatase or LDH at twice the normal upper limit
* Obvious clinical signs and symptoms of ongoing tissue infection (i.e., cellulitis) or bone infection (i.e., osteomyelitis)
* Female individuals are pregnant at time or intend to get pregnant during study time
* The individual has known allergies to antibiotics, such as penicillin and streptomycin
* The individual is an active smoker (smoke one or more cigarette a day)
* The individual has a history of a bleeding disorder or is taking blood thinner medication

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No